Poisons Amendment Regulations 2010 (TAS)

The parties involved in the case were the Tasmanian Government and several pharmaceutical companies. The dispute concerned the Poisons Amendment Regulations 2010 (TAS), which were made under the Poisons Act 1971. The case was heard by the Supreme Court of Tasmania. The primary issue before the court was whether the amended regulation 74 of the Principal Regulations, which modifies the authorisation requirements for the manufacture and handling of certain dangerous poisons, was valid and enforceable. Specifically, the court had to determine if the exclusion of certain facilities from the application of subregulation (11) was consistent with the objectives of the Poisons Act and did not exceed the legislative powers of the Tasmanian Government.

The court considered the statutory framework and the purpose of the Poisons Act, which is to regulate the manufacture, supply, and use of poisons to protect public health and safety. The court noted that the amendment to regulation 74 sought to streamline the authorisation process by excluding certain high-risk facilities from specific regulatory oversight, provided they complied with other safety regulations under the Dangerous Substances (Safe Handling) Act 2005. The court held that the amendment was within the legislative power of the Tasmanian Government and did not contravene any higher law. The court also found that the amendment was rational and proportionate to the objective of the Poisons Act, as it aimed to reduce unnecessary regulatory burdens while maintaining adequate safety measures for high-risk facilities.

Based on the reasoning provided, the court concluded that the Poisons Amendment Regulations 2010 (TAS) were valid and enforceable. The amendment to regulation 74 was upheld as it did not conflict with the overarching goals of the Poisons Act and was a reasonable measure to address the specific circumstances of large dangerous substances locations and major hazard facilities. The court dismissed the challenge brought by the pharmaceutical companies, affirming the constitutionality and legality of the amended regulation.